Position statementBeta-adrenergic blockers, immunotherapy, and skin testing
References (21)
- et al.
Fatalities from immunotherapy (IT) and skin testing (ST)
J Allergy Clin Immunol
(1987) - et al.
Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade
J Allergy Clin Immunol
(1981) - et al.
Military antishock trousers in a patient with adrenergic resistant anaphylaxis
Ann Emerg Med
(1984) - et al.
Biphasic and protracted anaphylaxis
J Allergy Clin Immunol
(1986) Risk of anaphylaxis in patients receiving beta-blocker drugs [Editorial]
J Allergy Clin Immunol
(1988)- et al.
Effects of beta-adrenergic calcium antagonists on the development of anaphylactoid reactions from radiographic contrast media during cardiac angiography
J Allergy Clin Immunol
(1987) - et al.
The safety of immunotherapy—a prospective study [Abstract]
J Allergy Clin Immunol
(1987) - et al.
Anaphylactic death in patient on beta blockers [Abstract]
Clin Invest Med
(1985) - et al.
Severe anaphylactoid reaction to radiographic contrast media: recurrences despite premedication with diphenhydramine and prednisone
JAMA
(1979) - et al.
Epinephrine-resistant anaphylaxis in a patient taking propranolol hydrochloride
Ann Allergy
(1981)
Cited by (33)
Immunotherapy: First do no harm
2005, Immunology and Allergy Clinics of North AmericaThe diagnosis and management of anaphylaxis: An updated practice parameter
2005, Journal of Allergy and Clinical ImmunologyUse of β-blockers during immunotherapy for Hymenoptera venom allergy
2005, Journal of Allergy and Clinical ImmunologyCitation Excerpt :Still, the number of patients on BB during immunotherapy, as in the previous prospective study,33 was relatively small, and conclusions for the general inconsiderate use of BB during VIT are certainly not justified. Theoretical and clinical evidence for a risk of severe and difficult to treat allergic reactions favored by the use of BB during IT is certainly strong.1-12,28-31 However, when confronted with a patient with a history of severe allergic sting reactions who is on BB, we have to estimate the risk of giving the BB during VIT against the risk of stopping the BB in the presence of cardiovascular disease or even the risk of renouncing VIT and continuing the BB.
Stinging and biting insect allergy: An Australian experience
2004, Annals of Allergy, Asthma and ImmunologyShould β-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis
2004, Journal of Allergy and Clinical ImmunologyThe pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction
2002, ChestCitation Excerpt :β1-Adrenoceptor blockers, which modulate the endogenous production of nitric oxide, are an interesting option, but more research is needed to better assess the impact of these drugs on patients with chronic airflow limitation. It must be stressed that the American Academy of Allergy and Immunology warned of a potential increased risk associated with the concomitant administration of allergen immunotherapy and β-blocking agents.41 The position statement recommended that, when possible, an equally safe and effective drug should substitute forβ -blockers.41